AU670962B2 - Method for antagonizing inositol 1,4,5-triphosphate - Google Patents

Method for antagonizing inositol 1,4,5-triphosphate Download PDF

Info

Publication number
AU670962B2
AU670962B2 AU48417/93A AU4841793A AU670962B2 AU 670962 B2 AU670962 B2 AU 670962B2 AU 48417/93 A AU48417/93 A AU 48417/93A AU 4841793 A AU4841793 A AU 4841793A AU 670962 B2 AU670962 B2 AU 670962B2
Authority
AU
Australia
Prior art keywords
document
international
date
search
inositol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48417/93A
Other languages
English (en)
Other versions
AU4841793A (en
Inventor
Kenneth A Stauderman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of AU4841793A publication Critical patent/AU4841793A/en
Application granted granted Critical
Publication of AU670962B2 publication Critical patent/AU670962B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyurethanes Or Polyureas (AREA)
AU48417/93A 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate Ceased AU670962B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95239392A 1992-09-28 1992-09-28
US952393 1992-09-28
PCT/US1993/008168 WO1994007507A1 (en) 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate

Publications (2)

Publication Number Publication Date
AU4841793A AU4841793A (en) 1994-04-26
AU670962B2 true AU670962B2 (en) 1996-08-08

Family

ID=25492868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48417/93A Ceased AU670962B2 (en) 1992-09-28 1993-08-30 Method for antagonizing inositol 1,4,5-triphosphate

Country Status (13)

Country Link
EP (1) EP0661982A1 (enExample)
JP (1) JPH08502068A (enExample)
KR (1) KR950703347A (enExample)
AU (1) AU670962B2 (enExample)
CA (1) CA2145681A1 (enExample)
HU (1) HUT70192A (enExample)
IL (1) IL107066A (enExample)
MX (1) MX9305933A (enExample)
NO (1) NO951163D0 (enExample)
NZ (1) NZ256178A (enExample)
TW (1) TW260663B (enExample)
WO (1) WO1994007507A1 (enExample)
ZA (1) ZA936978B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2978995A (en) * 1994-06-30 1996-01-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for treating cell proliferative disorders by modulating signal transduction
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
KR20000022273A (ko) 1996-06-27 2000-04-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 Il-8 수용체 길항제
CZ425598A3 (cs) * 1996-06-27 1999-08-11 Smithkline Beecham Corporation Antagonista IL-8 receptoru
CA2427757A1 (en) * 2000-11-09 2002-05-16 Contrimmune Biotechnology Inc. Therapeutic uses for ip3 receptor-mediated calcium channel modulators
AU2012301617A1 (en) 2011-09-02 2014-04-17 Salk Institute For Biological Studies CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB781479A (en) * 1953-08-27 1957-08-21 Ciba Ltd New polyureas and process for making them
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers

Also Published As

Publication number Publication date
NO951163L (no) 1995-03-27
ZA936978B (en) 1994-04-18
HUT70192A (en) 1995-09-28
MX9305933A (es) 1994-04-29
TW260663B (enExample) 1995-10-21
NO951163D0 (no) 1995-03-27
NZ256178A (en) 1997-03-24
IL107066A (en) 1998-01-04
WO1994007507A1 (en) 1994-04-14
CA2145681A1 (en) 1994-04-14
HU9500891D0 (en) 1995-05-29
IL107066A0 (en) 1993-12-28
KR950703347A (ko) 1995-09-20
EP0661982A1 (en) 1995-07-12
AU4841793A (en) 1994-04-26
JPH08502068A (ja) 1996-03-05

Similar Documents

Publication Publication Date Title
AU670962B2 (en) Method for antagonizing inositol 1,4,5-triphosphate
Leysen et al. Serotonergic component of neuroleptic receptors
Fairhurst et al. Interactions of D600 (methoxyverapamil) and local anesthetics with rat brain α-adrenergic and muscarinic receptors
Laduron et al. In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.
Merlos et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF)
DE69908414T2 (de) Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren
Hanson et al. UK‐78,282, a novel piperidine compound that potently blocks the Kv1. 3 voltage‐gated potassium channel and inhibits human T cell activation
Wu et al. Electrophysiological and binding studies on intact NCB-20 cells suggest presence of a low affinity sigma receptor.
Wander et al. Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro
CA2078572A1 (en) Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
Forray et al. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.
El-Fakahany et al. Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain
Aricioglu et al. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system
Nagasawa et al. . beta.-Substituted cysteines as sequestering agents for ethanol-derived acetaldehyde in vivo
Church et al. Interactions of dextromethorphan with theN-methyl-d-aspartate receptor-channel complex: single channel recordings
Sakauye et al. Agonist and antimineralocorticoid activities of spirolactones
Rowan et al. Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison with 5-hydroxytryptamine
Purcell et al. Characterisation of a functional polyamine site on rat mast cells: association with a NMDA receptor macrocomplex
Harris et al. Effects of dihydropyridine derivatives and anticonvulsant drugs on [3H] nitrendipine binding and calcium and sodium fluxes in brain
Syvälahti et al. Decrease in the number of rat brain dopamine and muscarinic receptors after chronic alcohol intake
Baumgold et al. Pharmacological differences between muscarinic receptors coupled to phosphoinositide turnover and those coupled to adenylate cyclase inhibition
IJzerman et al. Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine
Araujo et al. Characterization of [3H] AF‐DX 116 binding sites in the rat brain: Evidence for heterogeneity of muscarinic‐M2 receptor sites
Lee et al. Potent enhancement of [3H] nitrendipine binding in rat cerebral cortical and cardiac homogenates: a putative mechanism for the action of MDL 12,330 A.
Markstein et al. Serotonin-1C sites in the choroid plexus are not linked in a stimulatory or inhibitory way to adenylate cyclase